Filtros de búsqueda

Lista de obras de Yi-Long Wu

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.

artículo científico publicado en 2017

A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel.

artículo científico publicado en 2017

A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.

artículo científico publicado en 2008

A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).

artículo científico publicado en 2014

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).

artículo científico publicado en 2017

A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer

artículo científico publicado en 2020

A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.

artículo científico publicado en 2014

Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data

scientific article published on 15 September 2020

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

artículo científico publicado en 2014

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring mutations: subgroup analysis of the LUX-Lung 6 trial

article

An Autologous Therapeutic Dendritic Cell Vaccine Transfected with Total Lung Carcinoma RNA Stimulates Cytotoxic T Lymphocyte Responses Against Non-Small Cell Lung Cancer

article

Analysis of Differentially Expressed Proteins in Self-Paired Sera of Advanced Non-small Cell Lung Cancer Patients Responsive to Gefinitib

artículo científico publicado en 2009

Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

artículo científico publicado en 2015

BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification.

artículo científico publicado en 2013

BRAIN study: it is hard to draw a conclusion - Authors' reply.

artículo científico publicado en 2017

Bevacizumab plus chemotherapy for patients with advanced pulmonary adenocarcinoma harboring EGFR mutations

artículo científico publicado en 2017

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

article

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism

scientific article published on 26 May 2011

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis

artículo científico publicado en 2012

Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening

artículo científico publicado en 2017

Clinical characteristics and prognostic value of the KRAS G12C mutation in Chinese non-small cell lung cancer patients

artículo científico publicado en 2020

Clinical characteristics and sequence complexity of anaplastic lymphoma kinase gene fusions in Chinese lung cancer patients

artículo científico publicado en 2017

Clinical management of third-generation EGFR inhibitor-resistant patients with advanced non-small cell lung cancer: Current status and future perspectives

scientific article published on 13 June 2019

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.

artículo científico publicado en 2012

Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review

artículo científico publicado en 2017

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies

scientific article published on 09 October 2018

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

artículo científico publicado en 2009

Combinations of laminin 5 with PTEN, p-EGFR and p-Akt define a group of distinct molecular subsets indicative of poor prognosis in patients with non-small cell lung cancer

artículo científico publicado en 2012

Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy

scientific article published on 25 April 2007

Complete remission and fatal interstitial pneumonitis related to nab-paclitaxel in refractory small cell lung cancer: A case report and review of the literature

artículo científico publicado en 2012

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

article

Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version

artículo científico publicado en 2013

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

artículo científico publicado en 2013

Dacomitinib in NSCLC: a positive trial with little clinical impact - Authors' reply.

artículo científico publicado en 2018

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

artículo científico publicado en 2017

Detecting the spectrum of multigene mutations in non-small cell lung cancer by Snapshot assay.

artículo científico publicado en 2014

Detection of epidermal growth factor receptor mutations in non-small cell lung cancer tumor specimens from various ways by denaturing high-performance liquid chromatography

artículo científico publicado en 2010

Developing CSCO Lung Cancer Practice Guidelines Stratified by Resource Availability and Treatment Value

artículo científico publicado en 2016

Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort stud

scientific article published on 01 June 2020

Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients

artículo científico publicado en 2017

Disease flare after EGFR tyrosine kinase inhibitor cessation predicts poor survival in patients with non-small cell lung cancer

artículo científico publicado en 2013

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6).

artículo científico publicado en 2017

Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?

artículo científico publicado en 2017

Down-regulation of p16 and MGMT promotes the anti-proliferative and pro-apoptotic effects of 5-Aza-dC and radiation on cervical cancer cells.

artículo científico publicado en 2017

Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial.

artículo científico publicado en 2017

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer

artículo científico publicado en 2018

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

artículo científico publicado en 2017

EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas.

artículo científico publicado en 2012

EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients

artículo científico publicado en 2008

Effect of Dose Adjustments on the Safety and Efficacy of Afatinib in Chinese Patients with <i>EGFR-</i>Mutated Non-Small Cell Lung Cancer Who Participated in the LUX-Lung Clinical Trial Program

scientific article published on 07 December 2020

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.

artículo científico publicado en 2016

Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.

artículo científico publicado en 2010

Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study

artículo científico publicado en 2012

Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial

article

Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer

artículo científico publicado en 2014

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.

artículo científico publicado en 2014

Emerging challenges of advanced squamous cell lung cancer.

artículo científico publicado en 2016

Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).

artículo científico publicado en 2012

Epidermal Growth Factor Receptor Double Activating Mutations Involving Both Exons 19 and 21 Exist in Chinese Non-small Cell Lung Cancer Patients

article

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).

artículo científico publicado en 2013

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

artículo científico publicado en 2007

Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

artículo científico publicado en 2012

Erlotinib in the Second/Third Line Treatment of Patients with Advanced Non-small Cell Lung Cancer

artículo científico publicado en 2009

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

artículo científico publicado en 2011

Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer

artículo científico publicado en 2017

Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients.

artículo científico publicado en 2008

Familial association of lung cancer with liver cancer in first-degree relatives

scientific article published on 28 June 2019

Feasibility of computed tomography-guided core needle biopsy in producing state-of-the-art clinical management in Chinese lung cancer.

artículo científico publicado en 2014

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

scientific article published on 08 April 2019

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

artículo científico publicado en 2017

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

artículo científico publicado en 2014

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

artículo científico publicado en 2017

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

artículo científico publicado en 2017

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

artículo científico publicado en 2009

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

artículo científico publicado en 2008

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

artículo científico publicado en 2017

Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.

artículo científico publicado en 2010

Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia

scientific journal article

Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes

artículo científico publicado en 2021

Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer

scientific article published on 26 October 2020

Germline variation networks in the PI3K/AKT pathway corresponding to familial high-incidence lung cancer pedigrees

artículo científico publicado en 2020

HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component.

artículo científico publicado en 2010

Haem oxygenase-1 plays a central role in NNK-mediated lung carcinogenesis.

artículo científico publicado en 2008

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).

artículo científico publicado en 2011

High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients

artículo científico publicado en 2005

Higher expression of mRNA and protein of insulin-like growth factor binding protein-3 in old rat penile tissues: implications for erectile dysfunction

artículo científico publicado en 2011

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

artículo científico publicado en 2011

Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial

artículo científico publicado en 2013

Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status.

artículo científico publicado en 2012

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.

artículo científico publicado en 2010

Insulin-like growth factor-1 restores erectile function in aged rats: modulation the integrity of smooth muscle and nitric oxide-cyclic guanosine monophosphate signaling activity

artículo científico publicado en 2008

Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' reply

artículo científico publicado en 2013

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

artículo científico publicado en 2013

Involvement of discoidin domain 1 receptor in recurrence of hepatocellular carcinoma by genome-wide analysis.

artículo científico publicado en 2012

Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patie

artículo científico publicado en 2011

KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy

artículo científico publicado en 2012

Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy.

artículo científico publicado en 2014

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance.

artículo científico publicado en 2017

Lung Cancer Management in the Asia-Pacific Region: What's the Difference Compared with the United States and Europe? Results of the Second Asia Pacific Lung Cancer Conference

article

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.

artículo científico publicado en 2014

Lung cancer working group report

artículo científico publicado en 2010

Lung cancer: current therapies and new targeted treatments

artículo científico publicado en 2016

Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.

artículo científico publicado en 2014

MET expression plays differing roles in non-small-cell lung cancer patients with or without EGFR mutation.

artículo científico publicado en 2014

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

artículo científico publicado en 2009

Managing Pain in Patients With Cancer: The Chinese Good Pain Management Experience

artículo científico publicado en 2016

Meta-Analysis of First-Line Pemetrexed Plus Platinum Treatment in Compared to Other Platinum-Based Doublet Regimens in Elderly East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

artículo científico publicado en 2016

Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer

artículo científico publicado en 2017

Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients.

artículo científico publicado en 2017

Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib ⬇️

artículo científico publicado el 21 de enero de 2011

Multiple pulmonary chondromas in a young female patient: a component of Carney triad

artículo científico publicado en 2009

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

artículo científico publicado en 2013

Mutation of the BRAF genes in non-small cell lung cancer

artículo científico publicado en 2012

Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial

artículo científico publicado en 2012

Numbers or Stations: From Systematic Sampling to Individualized Lymph Node Dissection in Non–Small-Cell Lung Cancer

artículo científico publicado en 2017

Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

artículo científico publicado en 2017

Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed

artículo científico publicado en 2017

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.

artículo científico publicado en 2017

Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.

artículo científico publicado en 2012

Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy

artículo científico publicado en 2011

Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China.

scientific article published on 12 February 2014

Principles of biopsy in suspected lung cancer: priority still based on invasion in the era of targeted therapy?

artículo científico publicado en 2013

Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer

artículo científico publicado en 2014

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

artículo científico publicado en 2013

RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.

artículo científico publicado en 2010

Randomized Clinical Trial of Pembrolizumab Versus Chemotherapy for Previously Untreated Chinese Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-042 China Study

artículo científico publicado en 2020

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

artículo científico publicado en 2009

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.

artículo científico publicado en 2014

Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer

scientific article published on 25 July 2011

Reply to 'Concern on quality-of-life analysis in the OPTIMAL study' by Couraud et al.

artículo científico publicado en 2013

Responses to crizotinib in a patient with c-ros oncogene 1, receptor tyrosine kinase-positive advanced lung adenocarcinoma: A case report

artículo científico publicado en 2014

Retrospective analysis of prognostic factors in 205 patients with laryngeal squamous cell carcinoma who underwent surgical treatment.

artículo científico publicado en 2013

Reviewing the safety of erlotinib in non-small cell lung cancer ⬇️

artículo científico publicado el 8 de diciembre de 2010

Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study.

artículo científico publicado en 2013

Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study

artículo científico publicado en 2011

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

artículo científico publicado en 2010

Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies

scientific article published on 08 July 2019

Scientific Advances in Thoracic Oncology 2016.

artículo científico

Second-line erlotinib in patients with advanced non-small-cell lung cancer: subgroup analyses from the TRUST study.

artículo científico publicado en 2011

Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study

artículo científico publicado en 2012

Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations

artículo científico publicado en 2013

Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer.

artículo científico publicado en 2016

Supracricoid partial laryngectomy cricohyoidoepiglottopexy (SCPL-CHEP) versus vertical partial laryngectomy for the treatment of glottic carcinoma

scientific article published on 16 December 2012

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

artículo científico publicado en 2011

Systemic tunnel dissection of mediastinal lymph nodes without clamping via uniportal video-assisted thoracoscopic surgery.

artículo científico publicado en 2017

Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy.

artículo científico publicado en 2012

The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer

artículo científico publicado en 2009

The Impact of Smoking Status on the Efficacy of Erlotinib in Patients with Advanced Non-small Cell Lung Cancer

artículo científico publicado en 2009

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC.

artículo científico publicado en 2016

The changing landscape of clinical trial and approval processes in China.

artículo científico publicado en 2017

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer

artículo científico publicado en 2017

The prognostic value of micrometastasis in non-small cell lung cancer

artículo científico publicado en 2013

The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine

artículo científico publicado en 2007

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

scientific article published on 01 June 2020

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study

artículo científico publicado en 2013

Two-dose-level confirmatory study of the pharmacokinetics and tolerability of everolimus in Chinese patients with advanced solid tumors ⬇️

artículo científico publicado el 13 de enero de 2011

Unique Genetic Profiles from Cerebrospinal Fluid Cell-free DNA in Leptomeningeal Metastases of EGFR-mutant Non-Small Cell Lung Cancer: A New Medium of Liquid Biopsy

artículo científico publicado en 2018

Use of Bipolar Energy for Transurethral Resection of Superficial Bladder Tumors: Long-Term Results

Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients

artículo científico publicado en 2014

[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].

artículo científico publicado en 2012

[Clinical role of F-18 FDG PET/CT in differentiating malignant and benign pleural effusion in patients with lung cancer].

artículo científico publicado en 2012

[Establishment and its biological characteristics of patient-derived lung cancer xenograft models].

artículo científico publicado en 2010

[High resolution melting analysis for detecting p53 gene mutations in patients with non-small cell lung cancer].

artículo científico publicado en 2011

[Research progress in non-small cell lung cancer with concomitant EML4-ALK fusion gene and EGFR gene mutation].

artículo científico publicado en 2011

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda